Search Results for "Regeneron Pharmaceuticals"

High-Dose Aflibercept: 48-Week Data

Diana V. Do, MD, FASRS

Real-World Data for 8 mg Aflibercept

Vasileios Konidaris, MD, PhD

A Closer Look at 8 mg Aflibercept

David R. Chow, MD, FRCS(C)

Additional Considerations for Treating ROP

Faruk Orge, MD; Darius Moshfeghi, MD

Decision Factors in managing patients with ROP

Faruk Orge, MD; and Darius Moshfeghi, MD

ICROP Classification and ROP Treatment Guidelines

Faruk Orge, MD; and Darius Moshfeghi, MD

Protocol AC: Step Therapy in DME

Chirag D. Jhaveri, MD; and Prof. Ramin Tadayoni

A Treatment Paradigm for Wet AMD

Daniel F. Kiernan, MD, FACS; Prethy Rao, MD, MPH, FACS; Andrew M. Schimel, MD

The Role of Fluid Stability in Obtaining Disease Control

Diana V. Do, MD; David S. Chin Yee, MD; Esther L. Kim, MD; Charles C. Wykoff, MD, PhD

Treatment Durability

Diana V. Do, MD; David S. Chin Yee, MD; Esther L. Kim, MD; Charles C. Wykoff, MD, PhD

Phase 3 Clinical Trial Data for EYLEA HD® (aflibercept) Injection 8 mg for the Treatment of Wet AMD

Daniel F. Kiernan, MD, FACS; Prethy Rao, MD, MPH, FACS; Andrew M. Schimel, MD

Goals and Challenges in Treating Wet AMD and DME

Diana V. Do, MD; David S. Chin Yee, MD; Esther L. Kim, MD; Charles C. Wykoff, MD, PhD

Phase 2/3 Clinical Trial Data for EYLEA HD® (aflibercept) Injection 8 mg for the Treatment of DME

Daniel F. Kiernan, MD, FACS; Prethy Rao, MD, MPH, FACS; Andrew M. Schimel, MD

View More